ATE402709T1 - Neue tellurium-verbindungen und ihre verwendung als immunmodulatoren - Google Patents

Neue tellurium-verbindungen und ihre verwendung als immunmodulatoren

Info

Publication number
ATE402709T1
ATE402709T1 AT05779419T AT05779419T ATE402709T1 AT E402709 T1 ATE402709 T1 AT E402709T1 AT 05779419 T AT05779419 T AT 05779419T AT 05779419 T AT05779419 T AT 05779419T AT E402709 T1 ATE402709 T1 AT E402709T1
Authority
AT
Austria
Prior art keywords
immune modulators
tellurium compounds
new
new tellurium
compounds
Prior art date
Application number
AT05779419T
Other languages
English (en)
Inventor
Michael Albeck
Benjamin Sredni
Original Assignee
Biomas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomas Ltd filed Critical Biomas Ltd
Application granted granted Critical
Publication of ATE402709T1 publication Critical patent/ATE402709T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C395/00Compounds containing tellurium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT05779419T 2004-09-17 2005-09-15 Neue tellurium-verbindungen und ihre verwendung als immunmodulatoren ATE402709T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61066004P 2004-09-17 2004-09-17

Publications (1)

Publication Number Publication Date
ATE402709T1 true ATE402709T1 (de) 2008-08-15

Family

ID=35985262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05779419T ATE402709T1 (de) 2004-09-17 2005-09-15 Neue tellurium-verbindungen und ihre verwendung als immunmodulatoren

Country Status (11)

Country Link
US (5) US7709524B2 (de)
EP (3) EP1791535B1 (de)
JP (1) JP2008513439A (de)
AT (1) ATE402709T1 (de)
AU (1) AU2005283719A1 (de)
CA (3) CA2580642C (de)
DE (1) DE602005008622D1 (de)
ES (2) ES2614113T3 (de)
HK (1) HK1103355A1 (de)
PT (1) PT1796660T (de)
WO (3) WO2006030439A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007514732A (ja) 2003-12-18 2007-06-07 バイオマス リミテッド 神経変性過程の予防及び治療のためのテルル誘導体
NZ548988A (en) * 2004-01-22 2010-04-30 Biomas Ltd Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds
DE602005008622D1 (de) 2004-09-17 2008-09-11 Biomas Ltd Neue tellurium-verbindungen und ihre verwendung als immunmodulatoren
US20080260770A1 (en) * 2004-09-17 2008-10-23 Biomas Ltd. Use of Tellurium Compounds as Adjuvants
WO2006075314A2 (en) 2005-01-11 2006-07-20 Jemtex Ink Jet Printing Ltd. Inkjet printer and method of controlling same
WO2007032010A2 (en) * 2005-09-15 2007-03-22 Biomas Ltd. Use of tellurium compounds for protection from ultra-violet radiation
JP5028480B2 (ja) * 2006-06-01 2012-09-19 ノベラ ファルマ ソシエダッド リミターダ 手足症候群の治療のためのアロプリノールの使用
EP1862166A1 (de) * 2006-06-01 2007-12-05 Yolanda Rodemer Verwendung von Allopurinol zur behandlung von palmar-plantarer Erythrodysesthesie
US9216197B2 (en) 2006-09-11 2015-12-22 Biomas Ltd. Topical formulations of tellurium-containing compounds
US20100297256A1 (en) 2007-11-23 2010-11-25 Benjamin Sredni Methods and compositions for inhibiting integrins using tellurium-containing compounds
WO2009066301A2 (en) * 2007-11-23 2009-05-28 Biomas Ltd. Methods and compositions for treating pox virus with tellurium-containing compounds
EP2385758A4 (de) * 2009-01-08 2013-01-23 Biomas Ltd Tellurhaltige verbindungen zur manipulation des weiblichen fortpflanzungssystems nach einer chemotherapie und/oder strahlentherapie
EP2385757A4 (de) * 2009-01-08 2012-12-26 Biomas Ltd Tellurhaltige verbindungen zur manipulation der männlichen fruchtbarkeit nach einer chemotherapie und/oder strahlentherapie
EP2246057A1 (de) 2009-04-29 2010-11-03 Nobera Pharma, S.L. Verwendung von Allopurinol zur Behandlung der Hand-Fuß-Hautreaktion
WO2010146547A1 (en) * 2009-06-16 2010-12-23 Biomas Ltd. Tellurium-containing compounds for facilitating transplantation
MX2012003770A (es) 2009-09-30 2012-08-03 Harvard College Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
WO2012065065A1 (en) * 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016132366A1 (en) 2015-02-18 2016-08-25 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11730761B2 (en) 2016-02-18 2023-08-22 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
KR102549951B1 (ko) * 2017-04-28 2023-06-29 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유기 텔루륨 화합물 및 그의 제조 방법, 리빙 라디칼 중합 개시제, 비닐 중합체의 제조 방법, 그리고 비닐 중합체
MX2019015475A (es) 2017-06-30 2020-02-19 Univ California Composiciones y metodos para modular el crecimiento del cabello.
WO2019067860A1 (en) * 2017-09-29 2019-04-04 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH
JP2021042161A (ja) * 2019-09-11 2021-03-18 国立大学法人東海国立大学機構 脱毛剤、脱毛モデル動物及び白髪モデル動物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3369550A (en) * 1967-02-17 1968-02-20 Thomas A. Armao Cryogenic clamps
GB1427415A (en) 1973-09-21 1976-03-10 Armao T A Cryosurgical instruments
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4962207A (en) 1985-09-30 1990-10-09 Bar-Ilan University Organic derivatives of tellurium and selenium
US4761490A (en) * 1985-03-15 1988-08-02 Bar-Ilan University Organic derivatives of tellurium and selenium and their use to stimulate cytokine production
US5102908A (en) 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
US4752614A (en) 1985-09-30 1988-06-21 Bar-Ilan University Pharmaceutical compositions of tellerium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US5093135A (en) 1985-09-30 1992-03-03 Michael Albeck Compounds for the induction of in vivo and in vitro production of cytokines
US4764461A (en) * 1985-09-30 1988-08-16 Bar-Ilan University Tellurium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US4929739A (en) * 1988-03-24 1990-05-29 Bar-Ilan University Complexes of tellurium and selenium derivatives
DE4007473A1 (de) 1990-03-09 1991-09-12 Tomsk G Med I Kryoskalpell
US5271925A (en) * 1990-03-09 1993-12-21 Benjamin Sredni Method for protecting against the effects of radiation which is based on the administration of a selenium or tellurium based compound
US5213899A (en) * 1990-12-17 1993-05-25 General Electric Company Room temperature vulcanizable silicone compositions
US5262149A (en) * 1992-08-13 1993-11-16 Benjamin Sredni Method of treating or preventing alopecia
DE69507493T2 (de) 1994-09-01 1999-06-10 Upjohn Co Tirilazad parentale formulierung mit einem co-lösungsmittel
US5576347A (en) * 1994-11-14 1996-11-19 Sredni; Benjamin Method of treating gastric ulcers
AU699442B2 (en) 1994-12-15 1998-12-03 Baker Norton Pharmaceuticals, Inc. Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound
US5654328A (en) * 1994-12-15 1997-08-05 Sredni; Benjamin Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds
HU227920B1 (en) * 1998-03-19 2012-06-28 Vertex Pharma Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
US6428534B1 (en) * 1999-02-24 2002-08-06 Cryovascular Systems, Inc. Cryogenic angioplasty catheter
KR20020005665A (ko) * 1999-04-09 2002-01-17 추후보정 카스파제 저해제 및 그것의 용도
TR200200767T1 (tr) * 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
EP1289993B9 (de) * 2000-06-07 2008-08-20 Vertex Pharmaceuticals Incorporated Caspase-inhibitoren und ihre verwendungen
EP1292610A1 (de) 2000-06-19 2003-03-19 University Of Southern California Verfahren zur behandlung und vorbeugung von alopecia
US6747008B1 (en) 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
ES2283456T3 (es) * 2000-11-21 2007-11-01 Vertex Pharmaceuticals Incorporated Inhibidores de caspasa de imidazol y bencimidazol y sus usos.
US20030148970A1 (en) 2001-01-12 2003-08-07 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-4
JP4428926B2 (ja) * 2001-05-23 2010-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの使用
US6472381B1 (en) * 2001-10-12 2002-10-29 Biomas Inc. Method of treating psoriasis
IL146694A (en) 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
EP1539701A1 (de) * 2002-06-28 2005-06-15 Vertex Pharmaceuticals Incorporated Caspaseinhibitoren und deren verwendungen
US7612091B2 (en) * 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
JP2007514732A (ja) 2003-12-18 2007-06-07 バイオマス リミテッド 神経変性過程の予防及び治療のためのテルル誘導体
US9474453B2 (en) 2004-09-15 2016-10-25 Itamar Medical Ltd. Measuring blood flow and venous capacitance
DE602005008622D1 (de) 2004-09-17 2008-09-11 Biomas Ltd Neue tellurium-verbindungen und ihre verwendung als immunmodulatoren
US20080260770A1 (en) 2004-09-17 2008-10-23 Biomas Ltd. Use of Tellurium Compounds as Adjuvants

Also Published As

Publication number Publication date
ES2614113T3 (es) 2017-05-29
US8623908B2 (en) 2014-01-07
EP1802292A2 (de) 2007-07-04
WO2006030437A2 (en) 2006-03-23
CA2580643A1 (en) 2006-03-23
US20100081623A1 (en) 2010-04-01
CA2580804A1 (en) 2006-03-23
EP1802292A4 (de) 2008-02-13
CA2580642A1 (en) 2006-03-23
WO2006030439A3 (en) 2007-05-18
CA2580643C (en) 2018-06-12
EP1791535B1 (de) 2008-07-30
US7709524B2 (en) 2010-05-04
WO2006030437A3 (en) 2006-06-22
WO2006030438A3 (en) 2006-05-04
US7652065B2 (en) 2010-01-26
CA2580642C (en) 2014-09-02
EP1796660A2 (de) 2007-06-20
US20080015175A1 (en) 2008-01-17
EP1791535A2 (de) 2007-06-06
US20090269418A1 (en) 2009-10-29
WO2006030438A2 (en) 2006-03-23
DE602005008622D1 (de) 2008-09-11
HK1103355A1 (en) 2007-12-21
PT1796660T (pt) 2017-02-13
JP2008513439A (ja) 2008-05-01
EP1796660A4 (de) 2008-01-16
US20070298124A1 (en) 2007-12-27
ES2312012T3 (es) 2009-02-16
WO2006030439A2 (en) 2006-03-23
US20100233294A1 (en) 2010-09-16
AU2005283719A1 (en) 2006-03-23
EP1796660B1 (de) 2016-11-23

Similar Documents

Publication Publication Date Title
ATE402709T1 (de) Neue tellurium-verbindungen und ihre verwendung als immunmodulatoren
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
EA200702128A1 (ru) Фенильные и пиридильные модуляторы lta4h
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA201890903A1 (ru) Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
ATE489370T1 (de) Herstellung und verwendung von verbindungen als aspartylproteasehemmer
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
NO20061197L (no) Proteasominhibitorer og fremgangsmater for anvendelse av samme
ATE463490T1 (de) Histondeacetylase-hemmer
DE602005021320D1 (de) 3,5-disubstituierte 1h-pyrrolo ä2,3-bü pyridine als jnk-inhibitoren
DE602005022471D1 (de) Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
WO2007120626A3 (en) Uses and compositions for treatment of ankylosing spondylitis
ATE505460T1 (de) Indazolderivate als inhibitoren der hormon- sensitiven lipase
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
ATE490825T1 (de) Behandlung von mineralschlämmen mit verbesserter pflanzenwachstumsrehabilitation
ATE493439T1 (de) Monoklonale ykl-40-antikörper
ATE460923T1 (de) Lyophilisierung von virosomen
NO20075304L (no) Metode for avtagende forkalkning
WO2006023866A3 (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
DE502005007105D1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
ATE512120T1 (de) Anaerobe reinigung von abwasser
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
ATE519504T1 (de) Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties